HK Stock Market Move | ZAI LAB (09688) rose over 13%. In the second quarter, product revenue increased by 11% quarter-on-quarter. The second half of the year will see multiple pipeline catalysts.
Zai Ding Pharmaceuticals (09688) surged over 13%. As of the time of writing, it has risen by 12.11%, trading at HKD 16.29, with a transaction volume of HKD 69.7039 million.
ZAI LAB (09688) rose over 13%. As of the time of publication, it is up 12.11%, priced at HKD 16.29, with a trading volume of HKD 69.7039 million.
On the news front, on the evening of August 6, ZAI LAB announced its financial performance for the second quarter of 2026, along with recent product highlights and company progress. The financial report indicates that the total revenue for the company in the second quarter of 2026 was USD 106.3 million, with net product revenue of USD 105.8 million, reflecting an 11% quarter-on-quarter growth, driven by the stable performance of Zai Labog and the sustained sales growth of Aigamod.
Notably, the company has advanced multiple global oncology and immunology pipeline projects toward critical clinical and regulatory milestones, with several significant pipeline catalysts expected in the second half of 2026. Among these, global Phase 1 data for the combination of zoci and PD-L1 inhibitors for first-line small cell lung cancer (SCLC) will be announced at the 2026 ESMO conference; a registrational Phase 3 study is planned to start later this year. The global Phase 1/1b study of ZL-1503 continues to progress, with preliminary first-in-human data expected in the second half of 2026.
Related Articles
HK Stock Market Move | Biocytogen Pharmaceuticals-B (02315) surged nearly 6% as its net profit attributable to the parent company in the first half of the year is expected to increase more than fourfold. The two main business lines achieve a dual driving force.
The stock prices of Hong Kong-listed CXOs have risen collectively recently. After the profit warning, will MEDTIDE (03880) continue to decline against the market trend or bounce back from being oversold?
CMSC: The RAS track ushers in a genuine turning point, with a leap in core value in the field over the next three years.
HK Stock Market Move | Biocytogen Pharmaceuticals-B (02315) surged nearly 6% as its net profit attributable to the parent company in the first half of the year is expected to increase more than fourfold. The two main business lines achieve a dual driving force.
The stock prices of Hong Kong-listed CXOs have risen collectively recently. After the profit warning, will MEDTIDE (03880) continue to decline against the market trend or bounce back from being oversold?
CMSC: The RAS track ushers in a genuine turning point, with a leap in core value in the field over the next three years.
RECOMMEND
